Hair regrowth. Therapeutic agents.
Today there are new classes of hair growth promotors with proven efficacy. This article reviews the current state of the art agents for treatment of two of the most common forms of hair loss encountered in clinical practice, androgenetic alopecia and alopecia areata. Current therapeutic strategies are based on recent advances in the understanding of disordered hair growth. Practical treatment protocols are presented.
Shapiro
J
J
University of British Columbia Hair Research and Treatment Centre, Division of Dermatology, Vancouver, Canada.
Price
V H
VH
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000505:Alopecia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000506:Alopecia Areata / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000818:Animals; D000875:Anthralin / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002648:Child; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D018120:Finasteride / Q000627:therapeutic use; D006197:Hair / Q000187:drug effects* / Q000254:growth & development*; D006801:Humans; D008297:Male; D008914:Minoxidil / Q000627:therapeutic use; D011701:PUVA Therapy; D013148:Spironolactone / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000726:Androgen Antagonists; D000893:Anti-Inflammatory Agents; D004791:Enzyme Inhibitors; D013148:Spironolactone; D017373:Cyproterone Acetate; D018120:Finasteride; D008914:Minoxidil; D000875:Anthralin